1. Home
  2. BUDA vs EQ Comparison

BUDA vs EQ Comparison

Compare BUDA & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Buda Juice Inc. Common Stock

BUDA

Buda Juice Inc. Common Stock

N/A

Current Price

$5.30

Market Cap

76.1M

ML Signal

N/A

Logo Equillium Inc.

EQ

Equillium Inc.

SELL

Current Price

$1.06

Market Cap

89.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BUDA
EQ
Founded
2013
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.1M
89.4M
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
BUDA
EQ
Price
$5.30
$1.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
9
Target Price
★ $13.00
$8.56
AVG Volume (30 Days)
6.8K
★ 299.9K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.14
N/A
Revenue
$12,609,000.00
★ $41,095,000.00
Revenue This Year
$39.28
N/A
Revenue Next Year
$21.29
N/A
P/E Ratio
$37.93
★ N/A
Revenue Growth
★ 11.84
N/A
52 Week Low
$5.26
$1.04
52 Week High
$12.00
$6.20

Technical Indicators

Market Signals
Indicator
BUDA
EQ
Relative Strength Index (RSI) 30.36 33.53
Support Level N/A N/A
Resistance Level $7.86 $1.54
Average True Range (ATR) 0.58 0.13
MACD -0.13 -0.02
Stochastic Oscillator 3.33 6.09

Price Performance

Historical Comparison
BUDA
EQ

About BUDA Buda Juice Inc. Common Stock

Buda Juice Inc operates in a beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never heat-treated, pasteurized, never HPP- processed, never UV- treated and always cold.

About EQ Equillium Inc.

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Share on Social Networks: